Symic Biomedical, Inc. is a biotechnology company developing a novel class of compounds that target the extracellular matrix having broad applications in both acute and chronic diseases and disorders. An Alumni of JLab MBC San Francisco, the firm's development efforts are focused on chronic wound treatments,hemodialysis vascular access dysfunction in end-stage kidney diseas, and osteoarthritis. These therapeutics are inspired by naturally occurring macromolecules that play key regulatory roles within the extracellular matrix. Symic Bio currently has two clinical candidates, SB-030 initially targeting the prevention of peripheral vein graft failure and SB-061, directed at disease modification and pain management in the treatment of osteoarthritis. In addition, Symic Bio is also investigating applications in the areas of fibrosis, oncology and diseases of the central nervous system.